High Asymptomatic Carriage With the Omicron Variant in South AfricaNigel Garrett, Sufia Dadabhai, Glenda Gray et al.|Clinical Infectious Diseases|2022Cited by 81
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo Mgodi, Simbarashe Takuva, Srilatha Edupuganti et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 45
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly Karuna et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 26
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Bethany Coomes, Nandini Sane et al.|The Lancet HIV|2024Cited by 12
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D. Miner, Anya Luke-Kilolam, Allan C. deCamp et al.|EBioMedicine|2024Cited by 7